The narrower loss and extended cash runway into 2030 reduce near-term dilution risk, but the stock remains a binary event-driven biotech. Key catalysts to watch: Phase 2 nuzefatide data in pancreatic cancer and any partnership/out-licensing for zelenectide in mUC. The next major pipeline update will be at upcoming medical meetings.
Price Chart
Executive Summary
Bicycle Therapeutics reported Q2 2026 financial results with a net loss of $50.3M ($-0.72/share), narrowing from a $79.0M loss ($-1.14/share) in Q2 2025, driven by a 38% reduction in operating expenses following a strategic reprioritization and workforce reduction. The company highlighted encouraging clinical data for its lead programs nuzefatide and zelenectide at AACR and ASCO, and maintains a cash runway into 2030 with $510.1M in cash. The narrower loss and cost discipline are credit-positive, but the company remains a pre-revenue clinical-stage biotech with no approved products, making this a neutral-to-modestly-positive operational update.
Key Financial Metrics
Key Facts
- Net loss narrowed to $50.3M ($-0.72/share) in Q2 2026 from $79.0M ($-1.14/share) in Q2 2025.
- Cash and cash equivalents were $510.1M as of June 30, 2026, with expected cash runway into 2030.
- R&D expenses decreased 42% YoY to $41.2M, driven by reduced zelenectide program costs and workforce reduction.
- G&A expenses decreased 24% YoY to $14.0M due to lower professional fees and personnel costs.
- Phase 2 trial for nuzefatide in recurrent pancreatic cancer is actively enrolling; first patient dosed in April 2026.
- Duravelo-2 data for zelenectide in mUC showed 58% BICR-confirmed ORR at 27-week cutoff with differentiated safety profile.
- Company expanded Clinical Advisory Board with the addition of Professor Thomas Powles.
- Collaboration revenue was $0.6M for Q2 2026, down from $2.9M in Q2 2025.
Financial Impact
Net loss improved by $28.6M YoY to $50.3M; operating expenses reduced by $34.3M (38%) YoY to $55.2M
Risk Factors
- No approved products or revenue from product sales; collaboration revenue declining as partnerships wind down.
- Clinical trial failure risk for nuzefatide (EphA2) and zelenectide (Nectin-4) programs.
- Cash burn continues; $118M decrease in H1 2026 from $628M to $510M.
- Duravelo-2/3/4 trials deprioritized; zelenectide path to Phase 3 uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-088455 |
| Document: tm2621593d1_8k.htm | 0001104659-26-088455 |
| Document: 0001104659-26-088455-index-headers.html | 0001104659-26-088455 |
| Document: 0001104659-26-088455-index.html | 0001104659-26-088455 |
| Document: 0001104659-26-088455.txt | 0001104659-26-088455 |
| 8-K Data (Synthetic) | 0001104659-26-088455 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3/A | $3.73 | awaiting T+60 | — | $3.65 (−2.14%) |
Jul 30, 2026 12w ago | 8-K | $4.01 $3.55 | ▼ −11.47% | ▼ −13.94% | $3.65 (−8.98%) |
May 21, 2026 22w ago | 8-K | $4.55 $3.99 | ▼ −12.31% | ▼ −15.50% | $3.65 (−19.78%) |
Apr 20, 2026 27w ago | 8-K | $5.29 $4.22 | ▼ −20.23% | ▼ −27.00% | $3.65 (−31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers